High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study.

The accurate determination of HER-2 in invasive breast cancer has become a critical issue, particularly in the context of the results of recent trastuzumab (Herceptin((R))) adjuvant trials. This multicentre study evaluated inter-observer reproducibility in interpretation of HER-2 immunostains performed in different laboratories according to their in-house technique. A total of 74 HER-2 immunostains were evaluated by 16 pathologists and by a central review committee. As determined by central review, the HER-2 score was 0 in 33 cases (44%), 1+ in 10 cases (13%), 2+ in 9 cases (12%) and 3+ in 23 cases (31%). The overall kappa value was good (kappa=0.75). Agreement was excellent for the 0/1+ group (kappa=0.85) and for the 3+ group (kappa=0.82). As expected, the score 2+ group showed poor agreement (kappa=0.38). A quality assurance process showed that ring studies and adherence to national guidelines greatly improve inter-observer reproducibility.

[1]  M. Dowsett,et al.  Current Status of HER2 Testing , 2002, Oncology.

[2]  F. Penault-Llorca,et al.  Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. , 2003, International journal of oncology.

[3]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[4]  J. Fleiss.  Statistical methods for rates and proportions , 1974 .

[5]  Frédérique Penault-Llorca,et al.  [Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines]. , 2002, Annales de pathologie.

[6]  John J Spinelli,et al.  HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.

[7]  H. Tsuda,et al.  Evaluation of interobserver agreement in scoring immunohistochemical results of HER‐2/neu (c‐erbB‐2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma , 2002, Pathology international.

[8]  S J Schnitt,et al.  Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Larsimont,et al.  HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  E. Kay,et al.  C-erbB-2 immunostaining: problems with interpretation. , 1994, Journal of clinical pathology.

[11]  M. Dowsett,et al.  Current Perspectives on HER2 Testing: A Review of National Testing Guidelines , 2003, Modern Pathology.

[12]  A. Vincent-Salomon,et al.  Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS * Study , 2003, Histopathology.

[13]  H. Toutenburg.  Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S. , 1974 .

[14]  R. Nagle,et al.  Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. , 2002, Archives of pathology & laboratory medicine.

[15]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[16]  Thomas McGinn,et al.  Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic) , 2004, Canadian Medical Association Journal.

[17]  A. Vincent-Salomon,et al.  Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma , 2000, Modern Pathology.

[18]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[19]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[20]  N. Sneige,et al.  HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. , 2000, American journal of clinical pathology.

[21]  M. Untch,et al.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Visscher,et al.  Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization , 2000, Modern Pathology.

[24]  G. Farshid,et al.  Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. , 2003, Breast.

[25]  S. Paik,et al.  HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. , 2000, Journal of the National Cancer Institute.

[26]  A. Gown,et al.  HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. , 2000, American journal of clinical pathology.

[27]  Greg Yothers,et al.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.